Form 4: Oruka Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
Joana Goncalves, Chief Medical Officer of Oruka Therapeutics, Inc., sold 7,947 shares of common stock on September 15, 2026.
Summary
- Option exercise/conversion: acquired 3,500 Common Stock at $6.84 ($23,940) on September 15, 2026; holds 36,218 after (Direct).
- Option exercise/conversion: acquired 3,500 Common Stock at $7.80 ($27,300) on September 15, 2026; holds 39,718 after (Direct).
- Open-market sale: disposed of 2,384 Common Stock at $91.10 ($217,173) on September 15, 2026; holds 37,334 after (Direct).
- Open-market sale: disposed of 3,150 Common Stock at $92.03 ($289,890) on September 15, 2026; holds 34,184 after (Direct).
- Open-market sale: disposed of 1,366 Common Stock at $92.99 ($127,023) on September 15, 2026; holds 32,818 after (Direct).
- Open-market sale: disposed of 100 Common Stock at $94.22 ($9,422) on September 15, 2026; holds 32,718 after (Direct).
- Open-market sale: disposed of 947 Common Stock at $95.71 ($90,637) on September 15, 2026; holds 31,771 after (Direct).
- Option exercise/conversion: disposed of 3,500 Employee Stock Option (right to buy) on September 15, 2026; holds 193,563 after (Direct).
- Option exercise/conversion: disposed of 3,500 Employee Warrant (right to buy) on September 15, 2026; holds 164,992 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $734,145 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Joana Goncalves — Officer (Chief Medical Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-15 | Option exercise/conversion | Common Stock | 3,500 | $7 | $23.9K | 36,218 |
| 2026-09-15 | Option exercise/conversion | Common Stock | 3,500 | $8 | $27.3K | 39,718 |
| 2026-09-15 | Open-market sale | Common Stock | 2,384 | $91 | $217.2K | 37,334 |
| 2026-09-15 | Open-market sale | Common Stock | 3,150 | $92 | $289.9K | 34,184 |
| 2026-09-15 | Open-market sale | Common Stock | 1,366 | $93 | $127.0K | 32,818 |
| 2026-09-15 | Open-market sale | Common Stock | 100 | $94 | $9.4K | 32,718 |
| 2026-09-15 | Open-market sale | Common Stock | 947 | $96 | $90.6K | 31,771 |
| 2026-09-15 | Option exercise/conversion | Employee Stock Option (right to buy) | 3,500 | — | — | 193,563 |
| 2026-09-15 | Option exercise/conversion | Employee Warrant (right to buy) | 3,500 | — | — | 164,992 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-15 | Option exercise/conversion (3,500 shares) |
| 2026-09-15 | Option exercise/conversion (3,500 shares) |
| 2026-09-15 | Open-market sale (2,384 shares) |
| 2026-09-15 | Open-market sale (3,150 shares) |
| 2026-09-15 | Open-market sale (1,366 shares) |
| 2026-09-15 | Open-market sale (100 shares) |
| 2026-09-15 | Open-market sale (947 shares) |
| 2026-09-15 | Option exercise/conversion (3,500 shares) |
| 2026-09-15 | Option exercise/conversion (3,500 shares) |
Keywords
insider transaction, Form 4, ORKA, Oruka Therapeutics, Inc., bearish, Joana Goncalves
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.